Entresto®

Active substance

Sacubitril/Valsartan

Holder

Novartis Pharma

Status

Closed

Indication

Medical Need Program with Entreso (Sacubitril/Valsartan) for the treatment symptomatic chronic heart failure with reduced ejection fraction in adult patients.

Public documents

Approbation

Information for the patient

Informed consent

Lasst update

28/03/2017

Last updated on 13/02/2024